DE60231107D1 - Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems - Google Patents

Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems

Info

Publication number
DE60231107D1
DE60231107D1 DE60231107T DE60231107T DE60231107D1 DE 60231107 D1 DE60231107 D1 DE 60231107D1 DE 60231107 T DE60231107 T DE 60231107T DE 60231107 T DE60231107 T DE 60231107T DE 60231107 D1 DE60231107 D1 DE 60231107D1
Authority
DE
Germany
Prior art keywords
aüindole
tetrahydro
diseases
treatment
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231107T
Other languages
German (de)
English (en)
Inventor
Paul Hebeisen
Patrizio Mattei
Marc Muller
Hans Richter
Stephan Roever
Sven Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Ligand UK Research Ltd
Original Assignee
F Hoffmann La Roche AG
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Vernalis Research Ltd filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60231107D1 publication Critical patent/DE60231107D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60231107T 2001-03-13 2002-03-06 Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems Expired - Lifetime DE60231107D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106177.9A GB0106177D0 (en) 2001-03-13 2001-03-13 Piperazine derivatives
PCT/EP2002/002443 WO2002072584A2 (en) 2001-03-13 2002-03-06 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders

Publications (1)

Publication Number Publication Date
DE60231107D1 true DE60231107D1 (de) 2009-03-26

Family

ID=9910578

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231107T Expired - Lifetime DE60231107D1 (de) 2001-03-13 2002-03-06 Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems

Country Status (20)

Country Link
US (1) US6844345B2 (https=)
EP (1) EP1370561B1 (https=)
JP (1) JP4230225B2 (https=)
KR (1) KR100618748B1 (https=)
CN (1) CN1245405C (https=)
AR (1) AR035945A1 (https=)
AT (1) ATE422498T1 (https=)
AU (1) AU2002304833B2 (https=)
BR (1) BR0208111A (https=)
CA (1) CA2438596C (https=)
DE (1) DE60231107D1 (https=)
ES (1) ES2320739T3 (https=)
GB (1) GB0106177D0 (https=)
GT (1) GT200200048A (https=)
MX (1) MXPA03008338A (https=)
PA (1) PA8540801A1 (https=)
PE (1) PE20021043A1 (https=)
UY (1) UY27204A1 (https=)
WO (1) WO2002072584A2 (https=)
ZA (1) ZA200306613B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762132B1 (en) 2000-08-31 2004-07-13 Micron Technology, Inc. Compositions for dissolution of low-K dielectric films, and methods of use
JP4460450B2 (ja) 2002-06-19 2010-05-12 ビオヴィトルム・アクチボラゲット（プブリクト） 新規化合物、その使用および製造法
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
CN1980891B (zh) * 2004-05-03 2011-03-09 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
AU2006314649A1 (en) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
DE602006010433D1 (de) 2005-12-09 2009-12-24 Hoffmann La Roche Für die behandlung von obesitas geeignete tricyclische amidderivate
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2254886B1 (en) * 2008-03-28 2016-05-25 Nerviano Medical Sciences S.r.l. 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
JP5223035B2 (ja) * 2010-05-27 2013-06-26 国立大学法人 東京大学 抗炎症薬
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2013138568A1 (en) * 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
CN104203951B (zh) * 2012-03-16 2016-11-02 生命医药公司 肝x受体调节剂
UA113013C2 (uk) * 2012-08-06 2016-11-25 Ф. Хоффманн-Ля Рош Аг ПІПЕРАЗИНО[1,2-а]ІНДОЛ-1-ОНИ ТА [1,4]ДІАЗЕПІНО[1,2-а]ІНДОЛ-1-ОН
CN105246895B (zh) * 2013-04-02 2017-09-22 豪夫迈·罗氏有限公司 哌嗪并[1，2‑a]吲哚‑1‑酮和[1，4]二氮杂环庚烷并[1，2‑a]吲哚‑1‑酮
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN106317058B (zh) * 2016-08-17 2018-10-02 广东省微生物研究所 化合物dichotocejpin A及其制备方法和在制备治疗糖尿病药物中的应用
JOP20190239A1 (ar) 2017-04-19 2019-10-09 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات منها
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
WO2026006356A1 (en) * 2024-06-25 2026-01-02 Vanderbilt University 6-(pyrimidin-5-yl)-3,4-dihydropyrazino[l,2-a]imdol-l(2h)-one mcl-1 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3317524A (en) 1965-02-04 1967-05-02 American Home Prod Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
EP0572863A1 (de) * 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
AU3831495A (en) * 1994-10-20 1996-05-15 American Home Products Corporation Indole derivatives useful as serotonergic agents
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
WO2000009123A1 (en) 1998-08-14 2000-02-24 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors and chitosan
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
JP4180365B2 (ja) * 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体

Also Published As

Publication number Publication date
UY27204A1 (es) 2002-09-30
US6844345B2 (en) 2005-01-18
ZA200306613B (en) 2004-11-25
KR100618748B1 (ko) 2006-08-31
PA8540801A1 (es) 2005-02-04
GT200200048A (es) 2002-11-15
MXPA03008338A (es) 2003-12-11
ATE422498T1 (de) 2009-02-15
KR20030080255A (ko) 2003-10-11
BR0208111A (pt) 2004-03-02
CN1529706A (zh) 2004-09-15
EP1370561A2 (en) 2003-12-17
CA2438596A1 (en) 2002-09-19
ES2320739T3 (es) 2009-05-28
EP1370561B1 (en) 2009-02-11
WO2002072584A3 (en) 2003-01-03
WO2002072584A2 (en) 2002-09-19
PE20021043A1 (es) 2002-11-19
JP4230225B2 (ja) 2009-02-25
AR035945A1 (es) 2004-07-28
JP2004532823A (ja) 2004-10-28
GB0106177D0 (en) 2001-05-02
CN1245405C (zh) 2006-03-15
US20020169163A1 (en) 2002-11-14
AU2002304833B2 (en) 2006-05-04
CA2438596C (en) 2008-07-08

Similar Documents

Publication Publication Date Title
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60316538D1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE69927823D1 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60236218D1 (de) CCR5 Antagonisten verwendbar für die Behandlung von Aids
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
DE60133596D1 (de) S-Methyl-Dihydro-Ziprasidone für die Behandlung von Schizophrenie
DE60218529D1 (de) Isochroman verbindungen für die behandlung von cns-krankheiten
ATE357441T1 (de) Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne

Legal Events

Date Code Title Description
8364 No opposition during term of opposition